GSK-LSD1 is also tranylcypromine-based and is classified as a catalytic inhibitor of LSD1; however, recent work finds its anti-cancer effect is primarily due to allosteric disruption of the LSD1 interaction with AML oncoprotein Growth Factor Independent 1B (GFI1B) (38). The gene discussed is GFI1B; the disease is acute myeloid leukemia.